Close Menu

Tom Polen

Oct 03, 2018

Tom Polen, who currently serves as president of BD, has been promoted. He will now also serve as BD's Chief Operating Officer. Polen will be responsible for overseeing the firm's three operating segments, its new product development pipeline, and global operations including all manufacturing facilities and supply chain operations. The company has not had a COO since 2016, according to a statement.

More Like This

Sep 16, 2019

DermTech: Kevin Sun, Steven Kemper

DermTech has appointed Kevin Sun as CFO, treasurer, and secretary. He will be replacing CFO Steven Kemper, who will be retiring in October. Prior to DermTech, Sun served in various executive and management roles at DexCom, most recently as VP, corporate controller and treasury, interim CFO, and VP, Finance. Before DexCom, Sun held various roles at Biosite. 

Sep 13, 2019

Personalis: Karin Eastham

Menlo Park, California-based Personalis has appointed Karin Eastham as independent director to its board of directors. Eastham currently serves as board member for Geron, Veracyte, and Nektar Therapeutics. Prior to Personalis, Eastham served as executive VP and chief operating officer, as well as a member of the board of trustees, at the Burnham Institute for Medical Research from 2004 to her retirement in 2008. She previously served on the boards of Illumina, MorphoSys, Trius Therapeutics, Amylin Pharmacueticals, Genoptix, Tercica, and SGX Pharmaceuticals. 

Sep 13, 2019

QuantuMDx: Neil Butler

UK-based QuantuMDx has appointed Neil Butler as its non-executive director. Butler currently serves on the board of Nidor Dx, Radisens, and Spectromics. He previously served as chair and non-executive director for Atlast Genetics/Binx Health and Genomic Vision. 

Sep 12, 2019

Biocrates: Nicolas Schauer, Moritz Seuster, Wulf Fischer-Knuppertz

Austria-based Biocrates announced that it has appointed Nicolas Schauer as co-CEO and CSO along with Moritz Seuster as co-CEO and CFO. Wulf Fischer-Knuppertz is resigning from the firm's executive board and will continue to serve as a consultant. Prior to joining Biocrates, Schauer sold his own metabolite profiling company in 2017. 

Sep 12, 2019

ACMG Foundation: Brynn Levy, David Tilstra

Brynn Levy and David Tilstra have been elected to the board of directors of the ACMG Foundation for Genetic and Genomic Medicine, a nonprofit organization that facilitates the integration of genetics and genomics into medical practice.

Levy is a professor in the Department of Pathology & Cell Biology at Columbia University Irving Medical Center and co-director of the department's division of personalized genomic medicine. In addition, he is the medical director of the clinical cytogenetics laboratory of New York Presbyterian Hospital.

Tilstra is president emeritus of CentraCare Clinic. Until the end of 2018, he was the clinic's president, and before that, its medical director. Tilstra holds an MBA from the University of Colorado Denver, an MD from the University of Iowa College of Medicine, and an undergraduate degree in chemistry from Northwestern College of Orange City.

Sep 11, 2019

PharmGKB: Michelle Whirl-Carrillo

Michelle Whirl-Carrillo has been named director of PharmGKB. Since 2014, she has been associate director of the organization, and before that, she was assistant director and lead curator. Whirl-Carrillo holds a PhD in biophysics from Stanford University and an undergraduate degree in biology from MIT.

Sep 11, 2019

Waters: Mark Beaudouin, Keely Aleman

Waters has announced that Mark Beaudouin is retiring as senior VP, general counsel, and corporate secretary. Keeley Aleman, who is the firm's current VP, deputy general counsel and assistant secretary, will take his place. Prior to joining Waters in 2006, Aleman held corporate associate positions at Goodwin Proctor and Testa, Hurwitz & Thibeault. 

Sep 11, 2019

Syapse: Fletcher Payne

Fletcher Payne has been appointed as CFO of precision oncology firm Syapse. Payne joins Syapse from Catalyst Biosciences, where he was CFO since January 2015. He has previously held senior financial positions at CytomX Therapeutics, Plexxikon, Rinat Neuroscience Corporation, Dynavax Technologies Corporation, Cell Genesys, Abgenix, Sun Microsystems, and IBM. 

Sep 10, 2019

Epic Sciences: Joel Smith

San Diego-based Epic Sciences has appointed Joel Smith as its general counsel and executive VP of corporate development. Prior to Epic Sciences, Smith acted as managing counsel of Qualcomm Life. Smith has also served as senior executive and general counsel at biotech and life science companies including BioQ, Triad Therapeutics, and Sientra.


Sep 10, 2019

Quest Diagnostics: Manuel Méndez

Quest Diagnostics has named Manuel Méndez its senior VP and chief commercial officer, effective Oct. 7. Méndez is leaving Qiagen, where he currently is senior VP, global commercial operations and a member of the executive committee. Prior to joining Qiagen, he was executive VP Americas for BioMérieux.

Sep 10, 2019

SomaLogic: Patrick Terry

SomaLogic has appointed Patrick Terry as its chief commercial officer. He currently serves as a board member at MeMed Diagnostics, Inivata, GMPO, and PXE International. In addition, he previously cofounded Genomic Health.


Sep 09, 2019

Luminex: Dijuana Lewis

Luminex has elected Dijuana Lewis as an independent director to its board of directors, to the board's compensation and nominating committee, and to its corporate governance committee.

In a filing with the US Securities and Exchange Commission, Luminex reported that Lewis has served on various nonprofit and advisory boards and has consulted on healthcare related matters since her retirement from Aetna in April 2016.

She served Aetna as executive vice president, consumer products and enterprise marketing from October 2013 to April 2016. Prior to that, she served as senior vice president, health and wellness for Walmart Stores from March 2011 to October 2013. Further, Lewis previously served in a number of executive level positions of increasing responsibility with Anthem/Wellpoint from August 1994 to January 2011, including as the executive vice president and chief executive officer of its comprehensive health solutions division from October 2007 to January 2011.

Sep 06, 2019

Ubiquitome: Richard Creager

Richard Creager has been appointed to the board of directors of Aukland, New Zealand-based Ubiquitome. Creager most recently served as senior vice president of Beckman Coulter, where he was responsible for molecular diagnostics and led the introduction of the firm's Veris sample-to-answer molecular diagnostic system. He also served as Beckman's CSO, developing the technology and menu strategies for the company's immunoassay and molecular diagnostic businesses. He is currently CTO of nRichDX, a company developing liquid biopsy sample prep technology.

Sep 06, 2019

Shield Diagnostics: David Esposito

David Esposito has been appointed to the board of directors of Shield Diagnostics, a San Jose, California-based rapid molecular diagnostics firm developing assays for resistance-guided therapy. Esposito is currently CEO of ONL Therapeutics. He formerly served as CEO of Armune BioScience, a company that was sold to Exact Sciences in 2017, and he also served as President of Phadia US, an allergy and autoimmune diagnostics firm, playing a pivotal role in selling the business to Thermo Fisher Scientific in 2011.

Sep 06, 2019

BioMérieux: Kirk Ririe

Kirk Ririe, has retired from his position as bioMérieux's chief innovation officer and member of the firm's executive committee. Ririe will continue to act as a scientific advisor to the chairman and CEO.

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.